Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
Patients with metastatic pancreatic cancer that has progressed after receiving gemcitabine-based chemotherapy now have a new treatment option: irinotecan liposome in combination with fluorouracil and leucovorin.
-
In laboratories at NCI and around the world, researchers are using advanced genomic technologies to study the differences between cancer cells and normal cells, leading to new and more effective treatments for patients with cancer.
-
The FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1.
-
A recent NCI-sponsored conference brought together leading screening and cancer control researchers to discuss the state of the science of precision screening for five cancers.
-
A new study has found that patients with annual household incomes below $50,000 were less likely to participate in a cancer clinical trial than those with higher incomes.
-
Metastatic tumor cells are particularly sensitive to oxidative stress, and antioxidant supplementation increases their ability to grow and metastasize.
-
The FDA has approved nivolumab in combination with ipilimumab for advanced melanoma and nivolumab alone for advanced nonsquamous lung cancer.
-
Recognizing that complex factors underlie health disparities, NCI is taking a holistic approach in our efforts to address this serious public health issue.
-
Patients with advanced cancer may benefit from having discussions about their prognoses with their physicians.
-
A team of NCI researchers has reported that several types of gastrointestinal cancer have tumor-specific mutations that can be recognized by the immune system, thereby offering a new therapeutic opportunity for patients with these tumors.